Loading...
XSTO
BACTIb
Market cap56mUSD
Oct 09, Last price  
16.00SEK
1D
6.31%
1Q
-1.23%
Jan 2017
-5.33%
IPO
-50.31%
Name

Bactiguard Holding AB

Chart & performance

D1W1MN
XSTO:BACTIb chart
P/E
—
P/S
2.60
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.88%
Rev. gr., 5y
4.61%
Revenues
216m
-11.39%
127,010,000117,516,0004,382,000129,005,000126,733,000109,047,000131,420,000118,736,000147,458,000150,097,000184,987,000172,315,000169,486,000223,560,000203,990,000243,680,000215,918,000
Net income
-8m
L-73.69%
7,669,000-24,750,000-15,305,000-38,359,000-3,407,000-95,042,000-26,501,000-26,851,000-3,251,000-14,931,00016,256,000-38,389,000-58,773,000-52,877,000-138,382,000-29,815,000-7,844,000
CFO
-1m
L
79,764,00056,714,000-2,680,000-40,916,000-45,070,000-35,743,000-20,791,000-12,411,0006,117,000-16,691,00053,982,000702,0007,256,0003,062,000-52,331,00024,989,000-1,486,999

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Bactiguard Holding AB (publ), a Swedish-based global medical technology company, specializes in developing and supplying innovative solutions designed to prevent infections. Its primary objective is to mitigate healthcare-associated infections (HAIs) and reduce the global dependency on antibiotics. The core of Bactiguard's product line, known as Bactiguard Infection Protection (BIP), encompasses a range of coated medical devices. This includes various urinary catheters, such as the BIP Foley Catheter and the temperature-sensing BIP Foley TempSensor, all engineered to inhibit microbial adhesion and prevent urinary tract infections. Similarly, the BIP Central Venous Catheter and BIP Endotracheal Tube (with the BIP Endotracheal Tube Evac variant offering subglottic secretion drainage) work to reduce the risk of bloodstream and respiratory tract infections by minimizing biofilm formation. Beyond its BIP portfolio, the company offers a diverse array of other products, including Hydrocyn aqua advanced wound care for cleaning and debriding acute, chronic, and infected wounds, as well as general Bactiguard Wound Care items. It also provides a comprehensive selection of surgical sutures (natural absorbable, synthetic absorbable, non-absorbable, and specialty types), VigiMesh for hernia repair, and Hydrocyn aqua advanced disinfectant for sanitizing skin and surfaces. Additionally, Bactiguard supplies specialized orthopedic trauma implants featuring infection prevention technology under the ZNN Bactiguard brand, and the Aniocyn line of wound and skin care products for various pets. Bactiguard Holding AB (publ) was established in 2005 and maintains its headquarters in Tullinge, Sweden.

Related entities

Subsidiaries
Bactiguard AB

Key people

Stefan Grass
Deputy Chief Executive Officer · since 2020
Johan Rugfelt
Chief Operating Officer · since 2015
Nina Nilsson
Senior Vice President Sales & Marketing · since 2017
Gunilla Rydja
Director, Product Development and Market Access
Sathish Subramaniam
Director, Global Production & Supply Chain
Anna Martling
Director · since 2019
Chairman of the Board · since 2018
IPO date
Jun 19, 2014
Employees
220
Domiciled in
SE
Incorporated in
SE
Headquarters & legal address
Box 15
Tullinge, AB 146 21
SE
Address
Alfred Nobels Alle 150
Tullinge, AB 146 48
SE
Previous name
Quietus Advice K & W nr 770 AB

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT